Oric Pharmaceuticals financials
$13.37+0.75%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating income | -$143.0M | -$142.9M | -$110.8M | -$91.8M | -$78.9M | -$74.2M |
| Net income | -$129.5M | -$127.8M | -$100.7M | -$89.1M | -$78.7M | -$73.7M |
| Net margin | — | — | — | — | — | — |
| Diluted EPS | $-1.47 | $-1.83 | $-1.96 | $-2.25 | $-2.07 | $-3.36 |
| EBITDA | -$141.8M | -$141.8M | -$109.7M | -$90.8M | -$78.0M | -$73.2M |
| Operating cash flow | -$111.0M | -$112.7M | -$85.7M | -$75.1M | -$59.5M | -$45.3M |
| Free cash flow | -$111.7M | -$113.8M | -$86.5M | -$77.2M | -$60.5M | -$45.9M |
| Diluted shares | 87.8M | 69.7M | 51.5M | 39.7M | 38.0M | 21.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $45.7M | $59.4M | $23.4M | $66.8M | $226.0M | $78.4M |
| Short-term investments | $235.8M | $196.6M | $184.8M | $139.4M | $11.0M | $215.2M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $408.9M | $274.1M | $252.0M | $247.2M | $298.6M | $299.0M |
| Total liabilities | $24.5M | $31.0M | $27.9M | $24.8M | $25.7M | $9.2M |
| Shareholders' equity | $384.4M | $243.1M | $224.1M | $222.4M | $273.0M | $289.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology